- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05585320
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: IMM1104-101 Study Team
- Phone Number: (860) 321-1302
- Email: clinicaltrials@immuneering.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
Principal Investigator:
- Vincent Chung, MD
-
San Diego, California, United States, 92037
- Not yet recruiting
- University of California San Diego
-
Principal Investigator:
- Peter Vu, MD
-
Santa Monica, California, United States, 90403
- Recruiting
- Sarcoma Oncology Center
-
Principal Investigator:
- Sant Chawla, MD
-
-
Florida
-
Lake Mary, Florida, United States, 32746
- Recruiting
- Florida Cancer Specialists and Research Institute
-
Principal Investigator:
- Alexander Philipovskiy, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Principal Investigator:
- Sunandana Chandra, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana Farber Cancer Institute
-
Principal Investigator:
- Elizabeth Buchbinder, MD
-
-
New York
-
East Syracuse, New York, United States, 13057
- Recruiting
- Hematology Oncology Associates of Central New York
-
Principal Investigator:
- Steven Duffy, MD
-
New York, New York, United States, 10021
- Recruiting
- Weill Cornell Medicine
-
Principal Investigator:
- Anna Pavlick, DO
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Not yet recruiting
- Duke University Cancer Institute
-
Principal Investigator:
- Jeffrey Clarke, MD
-
-
Tennessee
-
Nashville, Tennessee, United States, 27203
- Recruiting
- SCRI Oncology Partners
-
Principal Investigator:
- Melissa Johnson, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Principal Investigator:
- Shubham Pant, MD
-
San Antonio, Texas, United States, 78229
- Recruiting
- NEXT Oncology
-
Principal Investigator:
- David Sommerhalder, MD
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- NEXT Oncology
-
Principal Investigator:
- Alex Spira, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must be ≥18 years of age
Must have histologically or cytologically confirmed diagnosis as follows:
- Monotherapy Phase 1: A locally advanced unresectable or metastatic solid tumor malignancy that harbors a RAS (KRAS, NRAS, or HRAS) activating mutation.
- Monotherapy Phase 2a: A locally advanced unresectable or metastatic solid tumor malignancies: pancreatic ductal adenocarcinoma (PDAC), RAS-mutant melanoma, or RAS-mutant non-small cell lung cancer (NSCLC)
- Combination therapy (both phases): A locally advanced unresectable or metastatic PDAC
Participants must be treatment naive or received prior systemic standard-of-care treatment as follows:
- Monotherapy Phase 1: received at least 1 line of systemic standard-of-care treatment for their advanced or metastatic disease
Monotherapy Phase 2a:
- First-line PDAC participants will have received no previous systemic anti-cancer therapy. Second-line PDAC participants will have received no more than one prior systemic anti-cancer therapy.
- First-line melanoma participants will have received no previous systemic anti-cancer therapy. Second- and third-line participants will have received and failed one or two prior systemic anti-cancer therapies, respectively.
- NSCLC participants will have received at least one and no more than two previous lines of systemic therapy.
- Combination therapy (both phases): PDAC participants will have received no previous systemic anti-cancer therapy for their advanced or metastatic disease.
- Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function
Exclusion Criteria:
- Inability to swallow oral medications
- Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases
- History or concurrent evidence of retinal vein occlusion (RVO) or current risk factors for RVO. History of serous retinopathy, retinal edema, or retinal pigment epithelial detachment (RPED)
- Impaired cardiovascular function or clinically significant cardiac disease
- History of rhabdomyolysis within 3 months prior to start of study treatment
- Active skin disorder requiring systemic treatment within 3 months prior to the start of study treatment
- Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMM-1-104 monotherapy (Treatment Group A)
IMM-1-104 monotherapy for first/second line pancreatic adenocarcinoma; first/second/third line melanoma; or second/third line non small cell lung cancer
|
Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met
Other Names:
|
Experimental: IMM-1-104 in combination with mGnP (Treatment Group B)
IMM-1-104 in combination with modified gemcitabine and nab-paclitaxel (mGnP) for first line pancreatic adenocarcinoma
|
Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met. Gemcitabine will be administered at a dose of 1000 mg/m^2 nab-Paclitaxel will be administered at a dose of 125 mg/m^2
Other Names:
|
Experimental: IMM-1-104 in combination with mFFX (Treatment Group C)
IMM-1-104 in combination with modified FOLFIRINOX (mFFX) for first line pancreatic adenocarcinoma
|
Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met. FOLFIRINOX will be administered as follows: Folinic Acid will be administered at 400 mg/m^2 Fluorouracil will be administered at 2400 mg/m^2 Irinotecan will be administered at 150 mg/m^2 Oxaliplatin will be administered at 85 mg/m^2
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Adverse Events
Time Frame: From treatment initiation through 30 days following the last IMM-1-104 dose
|
Number of participants with adverse events
|
From treatment initiation through 30 days following the last IMM-1-104 dose
|
Phase 1: Dose-Limiting Toxicities
Time Frame: The first 21 days of study treatment
|
Number of participants with dose-limiting toxicities
|
The first 21 days of study treatment
|
Phase 1: Recommended Phase 2 Dose (RP2D) candidate
Time Frame: Initiation of study treatment through 21 days (up to approximately 18 months)
|
Selection of candidate RP2D to take forward into Ph2a
|
Initiation of study treatment through 21 days (up to approximately 18 months)
|
Phase 2a: Overall Response Rate
Time Frame: After up to 48 weeks (12 cycles) of study treatment
|
The proportion of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR), based on RECIST 1.1 criteria
|
After up to 48 weeks (12 cycles) of study treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1/2a: Maximum Observed Plasma Concentration of IMM-1-104
Time Frame: After 12 weeks (3 Cycles) of study treatment
|
Cmax
|
After 12 weeks (3 Cycles) of study treatment
|
Phase 1/2a: Time to Reach Maximum Plasma Concentration of IMM-1-104
Time Frame: After 12 weeks (3 Cycles) of study treatment
|
Tmax
|
After 12 weeks (3 Cycles) of study treatment
|
Phase 1/2a: Area Under Plasma Concentration (AUC) Time Curve of IMM-1-104
Time Frame: After 12 weeks (3 Cycles) of study treatment
|
AUC0-t
|
After 12 weeks (3 Cycles) of study treatment
|
Phase 2a: Disease Control Rate (DCR)
Time Frame: After 16 weeks (4 Cycles) of study treatment
|
The proportion of participants who have a best overall response (BOR) of stable disease (SD) or better
|
After 16 weeks (4 Cycles) of study treatment
|
Phase 2a: Progression Free Survival (PFS)
Time Frame: Up to approximately 2 years
|
The time interval between study treatment start and disease progression or death due to any cause.
|
Up to approximately 2 years
|
Phase 2a: Duration of Response (DOR)
Time Frame: Up to approximately 2 years.
|
The time interval between an assessment of partial response (PR) or better and disease progression or death due to any cause.
|
Up to approximately 2 years.
|
Phase 2a: Landmark 3-Month Survival
Time Frame: After 3 months of study participation.
|
The proportion of participants who are still alive after three months on study.
|
After 3 months of study participation.
|
Phase 2a: Landmark 6-Month Survival
Time Frame: After 6 months of study participation.
|
The proportion of participants who are still alive after six months on study.
|
After 6 months of study participation.
|
Phase 2a: Overall Survival (OS)
Time Frame: Up to approximately 2 Years
|
The time interval between study treatment start and death due to any cause.
|
Up to approximately 2 Years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Vinny Hayreh, MD, Immuneering Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Skin Neoplasms
- Adenocarcinoma
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Folfirinox
- Gemcitabine
Other Study ID Numbers
- IMM1104-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Adenocarcinoma
-
Fudan UniversityUnknownStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Scandion Oncology A/SAlcedis GmbHRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic AdenocarcinomaDenmark, Germany
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Jean-Luc Van LaethemCelgene CorporationCompletedPancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally AdvancedBelgium
Clinical Trials on IMM-1-104 Monotherapy (Treatment Group A)
-
Sun Yat-sen UniversityUnknownGastric Cancer Stage IV | Cancer of StomachChina
-
Taejoon Pharmaceutical Co., Ltd.Active, not recruitingBowel PreparationKorea, Republic of
-
University of Erlangen-NürnbergFa. Reck MOTOmedCompleted
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
Qing XIeRecruitingChronic Hepatitis bChina
-
Biotronik SE & Co. KGBiotronik Japan, Inc.RecruitingImplantable Cardioverter Defibrillator(ICD)Japan
-
Fundacion para la Investigacion Biomedica del Hospital...Recruiting
-
University Hospital OstravaMinistry of Health, Czech Republic; Regional Council of the Moravian-Silesian...CompletedCritical Lower Limb Ischemia | Type-2 Diabetes MellitusCzechia
-
National Center for Research Resources (NCRR)Louisiana State University Health Sciences Center in New OrleansUnknownSystemic Lupus ErythematosusUnited States
-
Foundation University IslamabadCompleted